Summary of Study ST002976

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001852. The data can be accessed directly via it's Project DOI: 10.21228/M8B424 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002976
Study TitleMetabolomics Insights into Doxorubicin and 5-Fluorouracil Combination Therapy in Triple-Negative Breast Cancer: A Xenograft Model Study (Part 2)
Study TypeLC/MS/MS
Study SummaryBackground: Breast cancer is one of the most prevalent malignancies and a leading cause of death among women worldwide. Among its subtypes, triple-negative breast cancer (TNBC), which poses significant clinical challenges due to its aggressive behavior and limited treatment options. Aim: This study explored the effects of doxorubicin (DOX) and 5-fluorouracil (5-FU) as monotherapies and in combination on MDA-MB-231 xenograft model. Employing advanced metabolomics analysis, the study was designed to investigate molecular alterations triggered by these treatments. Methods: State-of-the-art metabolomics analysis using Ultra-high-performance liquid chromatography-electrospray ionization quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS) was conducted including comprehensive plasma and tumor tissue sample profiling. Results: The study explored alterations induced by DOX, 5-FU, and their combination treatment. Each treatment group exhibited unique metabolic profiles in plasma and tumor analysis. Univariate and enrichment analyses identified alterations in metabolic pathways, including glycine and serine metabolism, spermidine and spermine biosynthesis, and purine and pyrimidine pathways. The combination of DOX and 5-FU significantly influenced plasma and tumor metabolites. The comprehensive metabolic profiling of both plasma and tumor samples shed light on the intricate changes within the tumor microenvironment and their systemic implications. Conclusion: The study findings offer insights into the metabolic vulnerabilities of TNBC in vivo induced by the studied chemotherapeutics. These findings highlight the involved metabolites and metabolic pathways in the response of MDA-MB-231 cells to DOX, 5-FU, and their combination which advance our understanding of TNBC treatment strategies, offering new possibilities for enhancing therapeutic outcomes. This part of study involves comprehensive metabolomic profiling of the tumor tissue samples specifically and tumor growth assessment provide valuable insights into these treatments' efficacy and potential synergistic effects in TNBC.
Institute
Sharjah Institute for Medical Research
Last NameFacility
First NameCore
AddressM32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, UAE, Sharjah, 000, United Arab Emirates
Emailtims-tof@sharjah.ac.ae
Phone+971 6 5057656
Submit Date2023-11-08
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailLC-MS
Release Date2024-05-08
Release Version1
Core Facility Core Facility
https://dx.doi.org/10.21228/M8B424
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Mammal; Subject species: BALB/C nude mice (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA3232192B1-01-104815-fluorouracil
SA3232202A2-02-104805-fluorouracil
SA3232212A2-01-104795-fluorouracil
SA3232222B1-02-104825-fluorouracil
SA3232232B2-02-104845-fluorouracil
SA3232242B3-02-104865-fluorouracil
SA3232252B3-01-104855-fluorouracil
SA3232262A1-01-104775-fluorouracil
SA3232272B2-01-104835-fluorouracil
SA3232282A1-02-104785-fluorouracil
SA3232291A2-02-10467Doxorubicin
SA3232301A3-01-10468Doxorubicin
SA3232311A2-01-10466Doxorubicin
SA3232321A1-01-10464Doxorubicin
SA3232331A1-02-10465Doxorubicin
SA3232341B3-02-10475Doxorubicin
SA3232351A3-02-10469Doxorubicin
SA3232361B3-01-10474Doxorubicin
SA3232371B1-01-10470Doxorubicin
SA3232381B2-02-10473Doxorubicin
SA3232391B1-02-10471Doxorubicin
SA3232401B2-01-10472Doxorubicin
SA3232413B2-02-10495Doxorubicin + 5-fluorouracil
SA3232423B3-01-10496Doxorubicin + 5-fluorouracil
SA3232433B2-01-10494Doxorubicin + 5-fluorouracil
SA3232443B3-02-10497Doxorubicin + 5-fluorouracil
SA3232453A1-01-10488Doxorubicin + 5-fluorouracil
SA3232463B1-02-10493Doxorubicin + 5-fluorouracil
SA3232473A2-01-10490Doxorubicin + 5-fluorouracil
SA3232483A1-02-10489Doxorubicin + 5-fluorouracil
SA3232493A2-02-10491Doxorubicin + 5-fluorouracil
SA3232503B1-01-10492Doxorubicin + 5-fluorouracil
SA3232514B2-01-10507Positive Control
SA3232524B2-02-10508Positive Control
SA3232534B3-01-10509Positive Control
SA3232544B1-02-10506Positive Control
SA3232554B3-02-10510Positive Control
SA3232564A4-01-10503Positive Control
SA3232574A1-02-10500Positive Control
SA3232584A1-01-10499Positive Control
SA3232594A2-01-10501Positive Control
SA3232604A2-02-10502Positive Control
SA3232614A4-02-10504Positive Control
SA3232624B1-01-10505Positive Control
Showing results 1 to 44 of 44
  logo